Half-year Financial Report

/**/

RNS Number : 2045N Adalan Ventures PLC 30 December 2025  

Not for release or distribution, directly or indirectly, within, into or in the United States or to or for the account or benefit of persons in the United States, Australia, Canada, Japan or any other jurisdiction where such offer or sale would violate the relevant securities laws of such jurisdiction.   For Immediate Release 31st December 2025 Adalan Ventures Plc ("Adalan" or the "Company") Unaudited Interim results for 6 months ended 30 June 2025   Adalan Ventures plc (the 'Company' or 'Adalan'), announces its unaudited interim results for the 6 month period ended 30 June 2025.   The results follow at the bottom of this announcement.        Enquiries:

  Adalan Ventures Plc



Siro Cicconi

  Tel: +44 (0) 73 9377 9849





  This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.       Adalan Ventures plc Interim Condensed Consolidated Statement of profit or loss and Other Comprehensive Income for the six months ended 30 June  



Notes

Six months ended 30 June 2025 Unaudited £

Six months ended 30 June 2024 Unaudited £









Staff Costs



(90,825)

(114,464)

Operating expenses



(36,877)

(93,711)

Loss before income tax

 

(127,702)

(208,175)

  Income tax expense



-

-

Net loss

 

(127,702)

(208,175)









Net other comprehensive income that may be reclassified to profit or loss







Foreign exchange differences arising on translation into presentation currency



-

-





Total comprehensive loss

 

(127,702)

(208,175)

Adalan Ventures plc Interim Condensed Consolidated Statement of financial position as at  



Notes

30 June 2025 Unaudited £

31 December 2024 Audited £















Assets:







Cash and cash equivalents



2,597

1,823

Total Assets

 

2,597

1,823





























  Liabilities







Other liabilities



(967,830)

(859,354)

Advanced subscriptions for shares



(103,956)

(83,956)

Loan



(29,980)

(29,980)

Total liabilities

 

(1,101,766)

(973,290)

Net Assets

 

(1,099,169)

(971,467)

                       

  Equity







Capital and reserves:







Share capital

8

513,475

513,475

Deferred Share Capital



4,157,775

4,157,775

Share Premium

8

6,910,128

6,910,128

Share options Reserve



9,672

9,672

Accumulated deficit



(12,690,219)

(12,562,517)

Total equity

 

(1,099,169)

(971,467)

Total liabilities and equity

 

2,597

1,823

       Interim Condensed Statement of changes in shareholders' equity (Unaudited)  for the six months ended 30 June 2025  (unaudited)

 

Share capital £

      Deferred Share Capital £

Share Premium £

    Share    options Reserve £

 Accumulated  Deficit £

 Total Equity £



Balance as at 1 January 2025

513,475

  4,157,775

  6,910,128

  9,672

  (12,562,517)

  (971,467)

Issue of ordinary shares

-

-

-

-

-

-

Comprehensive loss for the period

-

  -

-

  -

(127,702)

(127,702)

Share-based payments

-

  -

-

          -

-

-

Balance as at 30 June 2025

513,475

  4,157,775

6,910,128

  9,672

(12,690,219)

(1,099,169)

  Interim Condensed Consolidated Statement of Cash Flows For the six months ended 30 June



Six months ended 30 June 2025 Unaudited £

Six months ended 30 June 2024 Unaudited £









Cash flows from operating activities





Loss for the period

(127,702)

(208,175)

Cash from operations

(127,702)

(208,175)







Net (increase)/decrease in operating assets





Change in receivables

-

-

Change in payables

96,476

155,723

Net change in working capital

96,476

155,723

Net cash flows from operating activities

(31,226)

(52,452))







Cash flows from financing activities





Advanced subscription of shares

20,000

-

Advancement of CLN

12,000

-

Net Cashflows from financing activities

32,000

-







Net change in cash and cash equivalents

774

(52,452)

  Cash and cash equivalents at the beginning of the year

1,823

58,116

Effects of Foreign exchange

-

1,000

Cash and cash equivalents at the end of the period

2,597

6,664

                                                                                                                                           1.     Basis of preparation   The condensed consolidated interim financial statements have been prepared using accounting policies consistent with International Financial Reporting Standards and in accordance with International Accounting Standard 34 Interim Financial Reporting. The condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2024, which have been prepared in accordance with International Financial Reporting Standards (IFRS).   The condensed consolidated interim financial statements set out above do not constitute statutory accounts within the meaning of the Companies Act 2006. They have been prepared on a going concern basis in accordance with the recognition and measurement criteria of International Financial Reporting Standards (IFRS). Statutory financial statements for the year ended 31 December 2024 were approved by the Board of Directors on 24 December 2025 and delivered to the Registrar of Companies. The report of the auditors on those financial statements was unqualified.   The condensed  consolidated interim financial statements of the Company have not been audited or reviewed by the Company's auditor, RPG Crouch Chapman LLP.   Going concern   The Financial Statements have been prepared on a going concern basis. The Directors consider that the Company requires additional funding in order to deliver on its plan to find and acquire an operating business and undertake a reverse take over. The Directors are of the view that its current cash reserves along with any funding that it will seek to raise would provide sufficient funds to undertake its operating activities for the foreseeable future. Should the company be unsuccessful in raising additional capital then there is a significant risk that it has the ability to continue as a going concern. The company has currently reduced its cash expenditure to a minimum.   Please refer to the going concern note in the annual report for the year ended 31 December 2024 for further information.   2.     Trade and other payables  



30 June 2025 Unaudited

31 Dec 2024 Audited



£

£

Trade payables

104,208

104,307

Accruals

840,147

746,466

CLN

12,000

-

Other payables 

11,475

8,581



967,830

859,354







Advanced subscriptions for shares of £103,956 at the period end (YE 2024 £83,956) represents funds advanced in the expectation of the issue of equity at a share price of 4p per share once the shares in the Company are able to be issued. This involves the commencement of trading in the company shares and issuance of a prospectus and or authority to allot shares being granted by shareholders at a general meeting and the annual authority to allot shares as determined by the FCA (currently 19.99%, due to increase to 75% on 19th January 2025).      3.     Subsequent events   The Company received further advanced subscriptions for shares following the period end totalling £200,000. The shares are expected to be issued following the lifting of suspension of the trading on the London Stock Exchange and publication of a prospectus.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  IR KBLFXELLLFBQ